Therefore, therapeutic strategies targeting NO in stroke must consider this complexity, aiming to inhibit detrimental NO production (mainly iNOS, possibly excessive nNOS) while preserving or enhancing beneficial eNOS function. The gene discussed is NOS1; the disease is stroke disorder.